Amgen melanoma drug shrinks tumors but fails secondary study goal
April 04, 2014 at 10:02 AM EDT
April 4 (Reuters) - Amgen Inc said its experimental drug to treat a deadly form of skin cancer shrank tumors, but did not significantly improve overall survival rates in patients enrolled in a late-stage study.